Clinical Trial: The Predictive Value of SII and CALLY Index for Treatment Efficacy and Prognosis of Immunotherapy Combined with Chemotherapy in HER-2-Negative Advanced Gastric Cancer (China)

Posted On: 2026-10-28

China, Oct. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The Predictive Value of SII and CALLY Index for Treatment Efficacy and Prognosis of Immunotherapy Combined with Chemotherapy in HER-2-Negative Advanced Gastric Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135272

Registration Time: 2026/10/28

Type: Observational study

Primary Sponsor: Linyi Tumor Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=303219

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: The Predictive Value of SII and CALLY Index for Treatment Efficacy and Prognosis of Immunotherapy Combined with Chemotherapy in HER-2-Negative Advanced Gastric Cancer (China)